Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Sitagliptin. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Novel omega-aminotransferase mutant enables high-yield sitagliptin intermediate production with 99% ee value and reduced solvent constraints for global supply chains.
Patent CN110540975B reveals high-efficiency biocatalytic route for sitagliptin precursors, offering superior stereoselectivity and reduced environmental impact for pharma supply chains.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediate synthesis, offering superior conversion rates and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediates. Achieves 90% conversion with superior purity and reduced environmental impact for pharma supply chains.
This patent details a novel biocatalytic route for sitagliptin intermediates offering high purity and yield. It enables significant cost reduction and supply chain reliability for pharmaceutical manufacturing partners.
Patent CN113801903B reveals enzymatic route for sitagliptin intermediate offering high purity and supply chain stability for global API manufacturers.
Patent CN108178761A reveals a mild PtO2 catalytic route for Sitagliptin. This method offers significant cost reduction and supply chain reliability for API manufacturing.
Novel asymmetric process for Sitagliptin ensures high yield and purity. Reliable pharmaceutical intermediates supplier offering cost reduction in API manufacturing and scalable solutions.
Patent CN106995807A enables high-purity Sitagliptin intermediate synthesis via recombinant transaminase, offering supply chain stability and cost efficiency.
Novel Rh-free synthesis of Sitagliptin phosphate ensuring high purity and cost efficiency for pharmaceutical supply chains.
Patent CN117843643A reveals a high-purity sitagliptin phosphate method. Reduced solvent use and simplified steps offer significant supply chain and cost advantages.
Novel industrial route for 2,4,5-trifluorophenylacetic acid using 2,4-dichlorotoluene. High yield, cost-effective manufacturing for DPP-4 inhibitor intermediates.
Novel Pd-catalyzed synthesis for Sitagliptin intermediate. High ee value, reduced waste, scalable production for pharma supply chains.
Patent CN106892832B details a high-purity Sitagliptin impurity synthesis. This method offers significant cost reduction in pharma manufacturing and reliable supply chain continuity.
Novel patent CN105017081A offers high-yield Sitagliptin intermediate synthesis. Reduces cost and improves supply chain reliability for pharmaceutical manufacturing.
Novel low-cost route for Sitagliptin intermediates via chiral resolution. Reduces catalyst costs and simplifies scale-up for API manufacturing.
Novel patent CN107129501B details cost-effective Sitagliptin synthesis using L-Aspartic acid, offering supply chain stability and high purity for pharmaceutical partners.
Patent CN114075201A reveals a novel 2-step route for Sitagliptin Impurity XGT062-05. Achieve high purity via Cope elimination, ensuring reliable API intermediate supply.
Patent CN115819260B reveals a novel synthesis route for sitagliptin intermediates offering cost reduction and high purity for pharmaceutical supply chains.